You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameIfosfamide
Accession NumberDB01181  (APRD00007)
TypeSmall Molecule
GroupsApproved
DescriptionIfosfamide is a chemotherapeutic agent chemically related to the nitrogen mustards and a synthetic analog of cyclophosphamide. It is active as an alkylating agent and an immunosuppresive agent.
Structure
Thumb
Synonyms
3-(2-Chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide
Ifosfamida
Ifosfamidum
Iphosphamide
Isofosfamide
Isophosphamide
Isosfamide
External Identifiers
  • Z4942
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Ifexinjection, powder, for solution1 g/20mLintravenousBaxter Healthcare Corporation1988-12-30Not applicableUs
Ifexinjection, powder, for solution3 g/60mLintravenousBaxter Healthcare Corporation1988-12-30Not applicableUs
Ifex (ifosfamide) 1 G/vialpowder for solution1 gintravenousBaxter Corporation2001-03-20Not applicableCanada
Ifex (ifosfamide) 3 G/vialpowder for solution3 gintravenousBaxter Corporation2001-01-25Not applicableCanada
Ifex Pws 1gm/vialpowder for solution1 gintravenousBristol Labs Division Of Bristol Myers Squibb1989-12-312001-04-09Canada
Ifex Pws 2g/vialpowder for solution2 gintravenousBristol Labs Division Of Bristol Myers Squibb1989-12-311997-08-14Canada
Ifex Pws 3gm/vialpowder for solution3 gintravenousBristol Labs Division Of Bristol Myers Squibb1989-12-312002-07-11Canada
Ifosfamideinjection, powder, for solution1 g/20mLintravenousBaxter Healthcare Corporation1988-12-30Not applicableUs
Ifosfamideinjection, powder, for solution3 g/60mLintravenousBaxter Healthcare Corporation1988-12-30Not applicableUs
Ifosfamide for Injectionpowder for solution3 gintravenousFresenius Kabi Canada LtdNot applicableNot applicableCanada
Ifosfamide for Injectionpowder for solution1 gintravenousFresenius Kabi Canada Ltd2003-04-15Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Ifosfamideinjection, solution50 mg/mLintravenousMylan Institutional LLC2012-11-27Not applicableUs
Ifosfamideinjection, solution50 mg/mLintravenousPfizer Laboratories Div Pfizer Inc.2012-11-27Not applicableUs
Ifosfamideinjection, powder, lyophilized, for solution1 g/1intravenousFresenius Kabi USA, LLC2003-01-28Not applicableUs
Ifosfamideinjection, solution50 mg/mLintravenousMylan Institutional LLC2012-11-27Not applicableUs
Ifosfamideinjection, solution50 mg/mLintravenousPfizer Laboratories Div Pfizer Inc.2012-11-27Not applicableUs
Ifosfamideinjection, solution50 mg/mLintravenousAPP Pharmaceuticals, LLC2009-09-30Not applicableUs
Ifosfamideinjection, solution1 g/20mLintravenousTeva Parenteral Medicines, Inc.2007-07-26Not applicableUs
Ifosfamideinjection, solution50 mg/mLintravenousMylan Institutional LLC2012-11-27Not applicableUs
Ifosfamideinjection, solution3 g/60mLintravenousTeva Parenteral Medicines, Inc.2007-07-26Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
CelofosCelon
CuantilTeva
HoloxanBaxter
MitoxanaBaxter
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIUM20QQM95Y
CAS number3778-73-2
WeightAverage: 261.086
Monoisotopic: 260.02481966
Chemical FormulaC7H15Cl2N2O2P
InChI KeyInChIKey=HOMGKSMUEGBAAB-UHFFFAOYSA-N
InChI
InChI=1S/C7H15Cl2N2O2P/c8-2-4-10-14(12)11(6-3-9)5-1-7-13-14/h1-7H2,(H,10,12)
IUPAC Name
3-(2-chloroethyl)-2-[(2-chloroethyl)amino]-1,3,2λ⁵-oxazaphosphinan-2-one
SMILES
ClCCNP1(=O)OCCCN1CCCl
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as isofamides. These are oxazaphospholanes containing the isofamide skeleton. isofamide is a heterocyclic compound made up of a 1,3,2-oxazaphospholane, where the phosphorus atom is part of a phosphodiamide group, and the oxazaphospholane is substituted by two haloalkyl chains.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassOxazaphosphinanes
Sub ClassIsofamides
Direct ParentIsofamides
Alternative Parents
Substituents
  • Isofamide
  • Phosphoric monoester diamide
  • Organic phosphoric acid derivative
  • Oxacycle
  • Azacycle
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Organochloride
  • Organohalogen compound
  • Alkyl halide
  • Alkyl chloride
  • Aliphatic heteromonocyclic compound
Molecular FrameworkAliphatic heteromonocyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationUsed as a component of various chemotherapeutic regimens as third-line therapy for recurrent or refractory germ cell testicular cancer. Also used as a component of various chemotherapeutic regimens for the treatment of cervical cancer, as well as in conjunction with surgery and/or radiation therapy in the treatment of various soft tissue sarcomas. Other indications include treatment of osteosarcoma, bladder cancer, ovarian cancer. small cell lung cancer, and non-Hodgkin's lymphoma.
PharmacodynamicsIfosfamide requires activation by microsomal liver enzymes to active metabolites in order to exert its cytotoxic effects. Activation occurs by hydroxylation at the ring carbon atom 4 to form the unstable intermediate 4-hydroxyifosfamide. This metabolite than rapidly degrades to the stable urinary metabolite 4-ketoifosfamide. The stable urinary metabolite, 4-carboxyifosfamide, is formed upon opening of the ring. These urinary metabolites have not been found to be cytotoxic. N, N-bis (2-chloroethyl)-phosphoric acid diamide (ifosphoramide) and acrolein are also found. The major urinary metabolites, dechloroethyl ifosfamide and dechloroethyl cyclophosphamide, are formed upon enzymatic oxidation of the chloroethyl side chains and subsequent dealkylation. It is the alkylated metabolites of ifosfamide that have been shown to interact with DNA. Ifosfamide is cycle-phase nonspecific.
Mechanism of actionThe exact mechanism of ifosfamide has not been determined, but appears to be similar to other alkylating agents. Ifosfamide requires biotransformation in the liver by mixed-function oxidases (cytochrome P450 system) before it becomes active. After metabolic activation, active metabolites of ifosfamide alkylate or bind with many intracellular molecular structures, including nucleic acids. The cytotoxic action is primarily through the alkylation of DNA, done by attaching the N-7 position of guanine to its reactive electrophilic groups. The formation of inter and intra strand cross-links in the DNA results in cell death.
Related Articles
AbsorptionNot Available
Volume of distribution

Ifosfamide volume of distribution (Vd) approximates the total body water volume, suggesting that distribution takes place with minimal tissue binding. Following intravenous administration of 1.5 g/m2 over 0.5 hour once daily for 5 days to 15 patients with neoplastic disease, the median Vd of ifosfamide was 0.64 L/kg on Day 1 and 0.72 L/kg on Day 5. When given to pediatric patients, the volume of distribution was 21±1.6 L/m^2.

Protein bindingIfosfamide shows little plasma protein binding.
Metabolism

Primarily hepatic. Ifosfamide is metabolized through two metabolic pathways: ring oxidation ("activation") to form the active metabolite, 4-hydroxy-ifosfamide and side-chain oxidation to form the inactive metabolites, 3-dechloro-ethylifosfamide or 2-dechloroethylifosfamide with liberation of the toxic metabolite, chloroacetaldehyde. Small quantities (nmol/mL) of ifosfamide mustard and 4-hydroxyifosfamide are detectable in human plasma. Metabolism of ifosfamide is required for the generation of the biologically active species and while metabolism is extensive, it is also quite variable among patients.

SubstrateEnzymesProduct
Ifosfamide
3-DechloroethylifosfamideDetails
Ifosfamide
2-DechloroethylifosfamideDetails
Ifosfamide
ChloroacetaldehydeDetails
Ifosfamide
4-HydroxyifosfamideDetails
4-Hydroxyifosfamide
Not Available
4-KetoifosfamideDetails
4-Hydroxyifosfamide
Not Available
aldoifosfamideDetails
4-Hydroxyifosfamide
Not Available
4-ThioifosfamideDetails
aldoifosfamide
Not Available
AlcoifosfamideDetails
aldoifosfamide
CarboxylifosfamideDetails
aldoifosfamide
Not Available
AcroleinDetails
aldoifosfamide
Not Available
Isophosphamide mustardDetails
Acrolein
Acrylic AcidDetails
Isophosphamide mustard
Not Available
Ifosforamide AziridiniumDetails
Route of eliminationIfosfamide is extensively metabolized in humans and the metabolic pathways appear to be saturated at high doses. After administration of doses of 5 g/m2 of 14C-labeled ifosfamide, from 70% to 86% of the dosed radioactivity was recovered in the urine, with about 61% of the dose excreted as parent compound. At doses of 1.6–2.4 g/m2 only 12% to 18% of the dose was excreted in the urine as unchanged drug within 72 hours.
Half life7-15 hours. The elimination half-life increase appeared to be related to the increase in ifosfamide volume of distribution with age.
Clearance
  • 2.4±0.33 L/h/m^2 [pediatric patients]
ToxicityLD50 (mouse) = 390-1005 mg/kg, LD50 (rat) = 150-190 mg/kg. Side effects include nausea, vomiting and myelosuppression. Toxic effects include central nervous system toxicity (confusion, hallucinations) and urotoxic effects (cystitis, blood in urine).
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Ifosfamide Action PathwayDrug actionSMP00448
Ifosfamide Metabolism PathwayDrug metabolismSMP00605
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9807
Blood Brain Barrier+0.9736
Caco-2 permeable-0.5411
P-glycoprotein substrateNon-substrate0.7098
P-glycoprotein inhibitor INon-inhibitor0.6204
P-glycoprotein inhibitor IINon-inhibitor0.9617
Renal organic cation transporterNon-inhibitor0.8135
CYP450 2C9 substrateNon-substrate0.7674
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateSubstrate0.5922
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.8835
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9723
Ames testAMES toxic0.9108
CarcinogenicityNon-carcinogens0.8903
BiodegradationNot ready biodegradable0.7807
Rat acute toxicity3.2294 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.8985
hERG inhibition (predictor II)Non-inhibitor0.8224
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Injection, powder, for solutionintravenous1 g/20mL
Injection, powder, for solutionintravenous3 g/60mL
Powder for solutionintravenous1 g
Powder for solutionintravenous3 g
Powder for solutionintravenous2 g
Injection, powder, lyophilized, for solutionintravenous1 g/1
Injection, solutionintravenous1 g/20mL
Injection, solutionintravenous3 g/60mL
Injection, solutionintravenous50 mg/mL
Prices
Unit descriptionCostUnit
Ifex-mesnex kit2709.98USD kit
Ifosfamide-mesna kit787.5USD kit
Ifex 3 gm vial489.13USD vial
Ifex 1 gm vial163.04USD vial
Ifosfamide 3 gm vial114.0USD vial
Ifosfamide 1 gm vial56.4USD vial
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5252341 No1994-07-162011-07-16Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point39-41 °CU.S. Patent 3,732,340.
water solubility3780 mg/LNot Available
logP0.86HANSCH,C ET AL. (1995)
Predicted Properties
PropertyValueSource
Water Solubility15.0 mg/mLALOGPS
logP0.57ALOGPS
logP0.097ChemAxon
logS-1.2ALOGPS
pKa (Strongest Acidic)13.24ChemAxon
pKa (Strongest Basic)0.12ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area41.57 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity58.48 m3·mol-1ChemAxon
Polarizability23.94 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
1D NMR1H NMR SpectrumNot Available
1D NMR13C NMR SpectrumNot Available
References
Synthesis Reference

U.S. Patent 3,732,340.

US3732340
General References
  1. Furlanut M, Franceschi L: Pharmacology of ifosfamide. Oncology. 2003;65 Suppl 2:2-6. [PubMed:14586139 ]
  2. Fleming RA: An overview of cyclophosphamide and ifosfamide pharmacology. Pharmacotherapy. 1997 Sep-Oct;17(5 Pt 2):146S-154S. [PubMed:9322882 ]
  3. Wagner T: Ifosfamide clinical pharmacokinetics. Clin Pharmacokinet. 1994 Jun;26(6):439-56. [PubMed:8070218 ]
  4. Allen LM, Creaven PJ, Nelson RL: Studies on the human pharmacokinetics of isophosphamide (NSC-109724). Cancer Treat Rep. 1976 Apr;60(4):451-8. [PubMed:1277221 ]
  5. Brade WP, Herdrich K, Varini M: Ifosfamide--pharmacology, safety and therapeutic potential. Cancer Treat Rev. 1985 Mar;12(1):1-47. [PubMed:3896483 ]
  6. Zalupski M, Baker LH: Ifosfamide. J Natl Cancer Inst. 1988 Jun 15;80(8):556-66. [PubMed:3286879 ]
  7. Willits I, Price L, Parry A, Tilby MJ, Ford D, Cholerton S, Pearson AD, Boddy AV: Pharmacokinetics and metabolism of ifosfamide in relation to DNA damage assessed by the COMET assay in children with cancer. Br J Cancer. 2005 May 9;92(9):1626-35. [PubMed:15827549 ]
  8. Lokiec F: Ifosfamide: pharmacokinetic properties for central nervous system metastasis prevention. Ann Oncol. 2006 May;17 Suppl 4:iv33-6. [PubMed:16702183 ]
  9. Schoenike SE, Dana WJ: Ifosfamide and mesna. Clin Pharm. 1990 Mar;9(3):179-91. [PubMed:2107997 ]
  10. Dechant KL, Brogden RN, Pilkington T, Faulds D: Ifosfamide/mesna. A review of its antineoplastic activity, pharmacokinetic properties and therapeutic efficacy in cancer. Drugs. 1991 Sep;42(3):428-67. [PubMed:1720382 ]
External Links
ATC CodesL01AA06
AHFS Codes
  • 10:00.00
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (293 KB)
Interactions
Drug Interactions
Drug
AbirateroneThe serum concentration of Ifosfamide can be increased when it is combined with Abiraterone.
AcenocoumarolIfosfamide may increase the anticoagulant activities of Acenocoumarol.
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Ifosfamide.
AmiodaroneThe serum concentration of the active metabolites of Ifosfamide can be reduced when Ifosfamide is used in combination with Amiodarone resulting in a loss in efficacy.
AprepitantThe serum concentration of Ifosfamide can be increased when it is combined with Aprepitant.
AripiprazoleThe serum concentration of Aripiprazole can be decreased when it is combined with Ifosfamide.
ArmodafinilThe metabolism of Ifosfamide can be decreased when combined with Armodafinil.
AtazanavirThe serum concentration of the active metabolites of Ifosfamide can be reduced when Ifosfamide is used in combination with Atazanavir resulting in a loss in efficacy.
AtomoxetineThe serum concentration of the active metabolites of Ifosfamide can be reduced when Ifosfamide is used in combination with Atomoxetine resulting in a loss in efficacy.
BevacizumabBevacizumab may increase the cardiotoxic activities of Ifosfamide.
BexaroteneThe serum concentration of the active metabolites of Ifosfamide can be reduced when Ifosfamide is used in combination with Bexarotene resulting in a loss in efficacy.
BoceprevirThe serum concentration of the active metabolites of Ifosfamide can be reduced when Ifosfamide is used in combination with Boceprevir resulting in a loss in efficacy.
BortezomibThe serum concentration of the active metabolites of Ifosfamide can be reduced when Ifosfamide is used in combination with Bortezomib resulting in a loss in efficacy.
BosentanThe serum concentration of Ifosfamide can be decreased when it is combined with Bosentan.
BusulfanThe risk or severity of adverse effects can be increased when Busulfan is combined with Ifosfamide.
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Ifosfamide.
CapecitabineThe metabolism of Ifosfamide can be decreased when combined with Capecitabine.
CarbamazepineThe serum concentration of the active metabolites of Ifosfamide can be increased when Ifosfamide is used in combination with Carbamazepine.
CelecoxibThe metabolism of Ifosfamide can be decreased when combined with Celecoxib.
CeritinibThe serum concentration of Ifosfamide can be increased when it is combined with Ceritinib.
ChloramphenicolThe metabolism of Ifosfamide can be decreased when combined with Chloramphenicol.
CholecalciferolThe metabolism of Ifosfamide can be decreased when combined with Cholecalciferol.
CimetidineThe metabolism of Ifosfamide can be decreased when combined with Cimetidine.
CitalopramThe metabolism of Ifosfamide can be decreased when combined with Citalopram.
ClarithromycinThe serum concentration of the active metabolites of Ifosfamide can be reduced when Ifosfamide is used in combination with Clarithromycin resulting in a loss in efficacy.
ClemastineThe serum concentration of the active metabolites of Ifosfamide can be reduced when Ifosfamide is used in combination with Clemastine resulting in a loss in efficacy.
ClopidogrelThe metabolism of Ifosfamide can be decreased when combined with Clopidogrel.
ClotrimazoleThe serum concentration of the active metabolites of Ifosfamide can be reduced when Ifosfamide is used in combination with Clotrimazole resulting in a loss in efficacy.
ClozapineThe risk or severity of adverse effects can be increased when Ifosfamide is combined with Clozapine.
CobicistatThe serum concentration of the active metabolites of Ifosfamide can be reduced when Ifosfamide is used in combination with Cobicistat resulting in a loss in efficacy.
ConivaptanThe serum concentration of Ifosfamide can be increased when it is combined with Conivaptan.
CrizotinibThe serum concentration of the active metabolites of Ifosfamide can be reduced when Ifosfamide is used in combination with Crizotinib resulting in a loss in efficacy.
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Ifosfamide.
CyclosporineThe serum concentration of the active metabolites of Ifosfamide can be reduced when Ifosfamide is used in combination with Cyclosporine resulting in a loss in efficacy.
DabrafenibThe serum concentration of the active metabolites of Ifosfamide can be reduced when Ifosfamide is used in combination with Dabrafenib resulting in a loss in efficacy.
DarunavirThe serum concentration of the active metabolites of Ifosfamide can be reduced when Ifosfamide is used in combination with Darunavir resulting in a loss in efficacy.
DasatinibThe serum concentration of Ifosfamide can be increased when it is combined with Dasatinib.
DeferasiroxThe serum concentration of Ifosfamide can be decreased when it is combined with Deferasirox.
DelavirdineThe serum concentration of the active metabolites of Ifosfamide can be reduced when Ifosfamide is used in combination with Delavirdine resulting in a loss in efficacy.
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Ifosfamide.
DesipramineThe metabolism of Ifosfamide can be decreased when combined with Desipramine.
DeslanosideDeslanoside may decrease the cardiotoxic activities of Ifosfamide.
DexamethasoneThe serum concentration of the active metabolites of Ifosfamide can be reduced when Ifosfamide is used in combination with Dexamethasone resulting in a loss in efficacy.
DicoumarolIfosfamide may increase the anticoagulant activities of Dicoumarol.
DigitoxinDigitoxin may decrease the cardiotoxic activities of Ifosfamide.
DigoxinDigoxin may decrease the cardiotoxic activities of Ifosfamide.
DihydroergotamineThe serum concentration of the active metabolites of Ifosfamide can be reduced when Ifosfamide is used in combination with Dihydroergotamine resulting in a loss in efficacy.
DiltiazemThe serum concentration of the active metabolites of Ifosfamide can be reduced when Ifosfamide is used in combination with Diltiazem resulting in a loss in efficacy.
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Ifosfamide.
DoxorubicinThe metabolism of Ifosfamide can be decreased when combined with Doxorubicin.
DoxycyclineThe serum concentration of the active metabolites of Ifosfamide can be reduced when Ifosfamide is used in combination with Doxycycline resulting in a loss in efficacy.
DronedaroneThe serum concentration of the active metabolites of Ifosfamide can be reduced when Ifosfamide is used in combination with Dronedarone resulting in a loss in efficacy.
EfavirenzThe serum concentration of the active metabolites of Ifosfamide can be reduced when Ifosfamide is used in combination with Efavirenz resulting in a loss in efficacy.
EnzalutamideThe serum concentration of the active metabolites of Ifosfamide can be increased when Ifosfamide is used in combination with Enzalutamide.
ErythromycinThe serum concentration of the active metabolites of Ifosfamide can be reduced when Ifosfamide is used in combination with Erythromycin resulting in a loss in efficacy.
Eslicarbazepine acetateThe serum concentration of the active metabolites of Ifosfamide can be reduced when Ifosfamide is used in combination with Eslicarbazepine acetate resulting in a loss in efficacy.
EsomeprazoleThe metabolism of Ifosfamide can be decreased when combined with Esomeprazole.
Ethyl biscoumacetateIfosfamide may increase the anticoagulant activities of Ethyl biscoumacetate.
EtravirineThe serum concentration of the active metabolites of Ifosfamide can be reduced when Ifosfamide is used in combination with Etravirine resulting in a loss in efficacy.
FelodipineThe metabolism of Ifosfamide can be decreased when combined with Felodipine.
FingolimodIfosfamide may increase the immunosuppressive activities of Fingolimod.
FloxuridineThe metabolism of Ifosfamide can be decreased when combined with Floxuridine.
FluconazoleThe serum concentration of the active metabolites of Ifosfamide can be reduced when Ifosfamide is used in combination with Fluconazole resulting in a loss in efficacy.
FluorouracilThe metabolism of Ifosfamide can be decreased when combined with Fluorouracil.
FluoxetineThe metabolism of Ifosfamide can be decreased when combined with Fluoxetine.
FluvastatinThe metabolism of Ifosfamide can be decreased when combined with Fluvastatin.
FluvoxamineThe serum concentration of the active metabolites of Ifosfamide can be reduced when Ifosfamide is used in combination with Fluvoxamine resulting in a loss in efficacy.
FosamprenavirThe serum concentration of the active metabolites of Ifosfamide can be reduced when Ifosfamide is used in combination with Fosamprenavir resulting in a loss in efficacy.
FosaprepitantThe serum concentration of Ifosfamide can be increased when it is combined with Fosaprepitant.
FosphenytoinThe serum concentration of the active metabolites of Ifosfamide can be increased when Ifosfamide is used in combination with Fosphenytoin.
Fusidic AcidThe serum concentration of Ifosfamide can be increased when it is combined with Fusidic Acid.
GemfibrozilThe metabolism of Ifosfamide can be decreased when combined with Gemfibrozil.
IdelalisibThe serum concentration of Ifosfamide can be increased when it is combined with Idelalisib.
ImatinibThe serum concentration of the active metabolites of Ifosfamide can be reduced when Ifosfamide is used in combination with Imatinib resulting in a loss in efficacy.
IndinavirThe serum concentration of the active metabolites of Ifosfamide can be reduced when Ifosfamide is used in combination with Indinavir resulting in a loss in efficacy.
IrbesartanThe metabolism of Ifosfamide can be decreased when combined with Irbesartan.
IsavuconazoniumThe serum concentration of the active metabolites of Ifosfamide can be reduced when Ifosfamide is used in combination with Isavuconazonium resulting in a loss in efficacy.
IsoniazidThe metabolism of Ifosfamide can be decreased when combined with Isoniazid.
IsradipineThe serum concentration of the active metabolites of Ifosfamide can be reduced when Ifosfamide is used in combination with Isradipine resulting in a loss in efficacy.
ItraconazoleThe serum concentration of the active metabolites of Ifosfamide can be reduced when Ifosfamide is used in combination with Itraconazole resulting in a loss in efficacy.
IvacaftorThe serum concentration of Ifosfamide can be increased when it is combined with Ivacaftor.
KetoconazoleThe serum concentration of the active metabolites of Ifosfamide can be reduced when Ifosfamide is used in combination with Ketoconazole resulting in a loss in efficacy.
LapatinibThe metabolism of Ifosfamide can be decreased when combined with Lapatinib.
LeflunomideThe risk or severity of adverse effects can be increased when Ifosfamide is combined with Leflunomide.
LeflunomideThe metabolism of Ifosfamide can be decreased when combined with Leflunomide.
LopinavirThe serum concentration of the active metabolites of Ifosfamide can be reduced when Ifosfamide is used in combination with Lopinavir resulting in a loss in efficacy.
LosartanThe metabolism of Ifosfamide can be decreased when combined with Losartan.
LovastatinThe serum concentration of the active metabolites of Ifosfamide can be reduced when Ifosfamide is used in combination with Lovastatin resulting in a loss in efficacy.
LuliconazoleThe serum concentration of Ifosfamide can be increased when it is combined with Luliconazole.
LumacaftorThe serum concentration of Ifosfamide can be decreased when it is combined with Lumacaftor.
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Ifosfamide.
MifepristoneThe serum concentration of the active metabolites of Ifosfamide can be reduced when Ifosfamide is used in combination with Mifepristone resulting in a loss in efficacy.
MitotaneThe serum concentration of the active metabolites of Ifosfamide can be increased when Ifosfamide is used in combination with Mitotane.
MoclobemideThe metabolism of Ifosfamide can be decreased when combined with Moclobemide.
ModafinilThe serum concentration of the active metabolites of Ifosfamide can be reduced when Ifosfamide is used in combination with Modafinil resulting in a loss in efficacy.
NafcillinThe serum concentration of the active metabolites of Ifosfamide can be reduced when Ifosfamide is used in combination with Nafcillin resulting in a loss in efficacy.
NatalizumabThe risk or severity of adverse effects can be increased when Ifosfamide is combined with Natalizumab.
NefazodoneThe serum concentration of the active metabolites of Ifosfamide can be reduced when Ifosfamide is used in combination with Nefazodone resulting in a loss in efficacy.
NelfinavirThe serum concentration of the active metabolites of Ifosfamide can be reduced when Ifosfamide is used in combination with Nelfinavir resulting in a loss in efficacy.
NetupitantThe serum concentration of Ifosfamide can be increased when it is combined with Netupitant.
NevirapineThe serum concentration of the active metabolites of Ifosfamide can be reduced when Ifosfamide is used in combination with Nevirapine resulting in a loss in efficacy.
NicardipineThe metabolism of Ifosfamide can be decreased when combined with Nicardipine.
NicotineThe metabolism of Ifosfamide can be decreased when combined with Nicotine.
NilotinibThe serum concentration of the active metabolites of Ifosfamide can be reduced when Ifosfamide is used in combination with Nilotinib resulting in a loss in efficacy.
NintedanibThe serum concentration of Nintedanib can be decreased when it is combined with Ifosfamide.
OlaparibThe serum concentration of the active metabolites of Ifosfamide can be reduced when Ifosfamide is used in combination with Olaparib resulting in a loss in efficacy.
OmeprazoleThe metabolism of Ifosfamide can be decreased when combined with Omeprazole.
OsimertinibThe serum concentration of Ifosfamide can be increased when it is combined with Osimertinib.
OuabainOuabain may decrease the cardiotoxic activities of Ifosfamide.
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Ifosfamide.
PalbociclibThe serum concentration of Ifosfamide can be increased when it is combined with Palbociclib.
PantoprazoleThe metabolism of Ifosfamide can be decreased when combined with Pantoprazole.
ParoxetineThe metabolism of Ifosfamide can be decreased when combined with Paroxetine.
PentobarbitalThe serum concentration of the active metabolites of Ifosfamide can be increased when Ifosfamide is used in combination with Pentobarbital.
PhenindioneIfosfamide may increase the anticoagulant activities of Phenindione.
PhenobarbitalThe serum concentration of the active metabolites of Ifosfamide can be increased when Ifosfamide is used in combination with Phenobarbital.
PhenprocoumonIfosfamide may increase the anticoagulant activities of Phenprocoumon.
PhenytoinThe serum concentration of the active metabolites of Ifosfamide can be increased when Ifosfamide is used in combination with Phenytoin.
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Ifosfamide.
PioglitazoneThe metabolism of Ifosfamide can be decreased when combined with Pioglitazone.
PosaconazoleThe serum concentration of the active metabolites of Ifosfamide can be reduced when Ifosfamide is used in combination with Posaconazole resulting in a loss in efficacy.
PrimidoneThe serum concentration of the active metabolites of Ifosfamide can be increased when Ifosfamide is used in combination with Primidone.
PyrimethamineThe metabolism of Ifosfamide can be decreased when combined with Pyrimethamine.
QuazepamThe serum concentration of Ifosfamide can be increased when it is combined with Quazepam.
QuinineThe metabolism of Ifosfamide can be decreased when combined with Quinine.
RabeprazoleThe metabolism of Ifosfamide can be decreased when combined with Rabeprazole.
Rabies vaccineThe risk or severity of adverse effects can be increased when Ifosfamide is combined with Rabies vaccine.
RanolazineThe serum concentration of the active metabolites of Ifosfamide can be reduced when Ifosfamide is used in combination with Ranolazine resulting in a loss in efficacy.
RifabutinThe serum concentration of the active metabolites of Ifosfamide can be increased when Ifosfamide is used in combination with Rifabutin.
RifampicinThe serum concentration of the active metabolites of Ifosfamide can be increased when Ifosfamide is used in combination with Rifampicin.
RifapentineThe serum concentration of the active metabolites of Ifosfamide can be increased when Ifosfamide is used in combination with Rifapentine.
RitonavirThe serum concentration of the active metabolites of Ifosfamide can be reduced when Ifosfamide is used in combination with Ritonavir resulting in a loss in efficacy.
RoflumilastRoflumilast may increase the immunosuppressive activities of Ifosfamide.
RosiglitazoneThe metabolism of Ifosfamide can be decreased when combined with Rosiglitazone.
SaquinavirThe serum concentration of the active metabolites of Ifosfamide can be reduced when Ifosfamide is used in combination with Saquinavir resulting in a loss in efficacy.
SaxagliptinThe serum concentration of Saxagliptin can be decreased when it is combined with Ifosfamide.
SecobarbitalThe metabolism of Ifosfamide can be increased when combined with Secobarbital.
SertralineThe metabolism of Ifosfamide can be decreased when combined with Sertraline.
SildenafilThe serum concentration of the active metabolites of Ifosfamide can be reduced when Ifosfamide is used in combination with Sildenafil resulting in a loss in efficacy.
SiltuximabThe serum concentration of Ifosfamide can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Ifosfamide can be increased when it is combined with Simeprevir.
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Ifosfamide.
SorafenibThe metabolism of Ifosfamide can be decreased when combined with Sorafenib.
St. John's WortThe serum concentration of Ifosfamide can be decreased when it is combined with St. John's Wort.
StiripentolThe serum concentration of Ifosfamide can be increased when it is combined with Stiripentol.
SulfadiazineThe metabolism of Ifosfamide can be decreased when combined with Sulfadiazine.
SulfamethoxazoleThe metabolism of Ifosfamide can be decreased when combined with Sulfamethoxazole.
SulfisoxazoleThe serum concentration of the active metabolites of Ifosfamide can be reduced when Ifosfamide is used in combination with Sulfisoxazole resulting in a loss in efficacy.
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Ifosfamide.
TamoxifenThe metabolism of Ifosfamide can be decreased when combined with Tamoxifen.
TelaprevirThe serum concentration of the active metabolites of Ifosfamide can be reduced when Ifosfamide is used in combination with Telaprevir resulting in a loss in efficacy.
TelithromycinThe serum concentration of the active metabolites of Ifosfamide can be reduced when Ifosfamide is used in combination with Telithromycin resulting in a loss in efficacy.
TeriflunomideThe metabolism of Ifosfamide can be decreased when combined with Teriflunomide.
ThiotepaThe metabolism of Ifosfamide can be decreased when combined with Thiotepa.
TicagrelorThe metabolism of Ifosfamide can be decreased when combined with Ticagrelor.
TiclopidineThe serum concentration of the active metabolites of Ifosfamide can be reduced when Ifosfamide is used in combination with Ticlopidine resulting in a loss in efficacy.
TocilizumabThe serum concentration of Ifosfamide can be decreased when it is combined with Tocilizumab.
TofacitinibIfosfamide may increase the immunosuppressive activities of Tofacitinib.
TolbutamideThe metabolism of Ifosfamide can be decreased when combined with Tolbutamide.
TopiramateThe metabolism of Ifosfamide can be decreased when combined with Topiramate.
TranylcypromineThe metabolism of Ifosfamide can be decreased when combined with Tranylcypromine.
TrastuzumabTrastuzumab may increase the neutropenic activities of Ifosfamide.
TrimethoprimThe metabolism of Ifosfamide can be decreased when combined with Trimethoprim.
Valproic AcidThe metabolism of Ifosfamide can be decreased when combined with Valproic Acid.
ValsartanThe metabolism of Ifosfamide can be decreased when combined with Valsartan.
VenlafaxineThe serum concentration of the active metabolites of Ifosfamide can be reduced when Ifosfamide is used in combination with Venlafaxine resulting in a loss in efficacy.
VerapamilThe serum concentration of the active metabolites of Ifosfamide can be reduced when Ifosfamide is used in combination with Verapamil resulting in a loss in efficacy.
VoriconazoleThe serum concentration of the active metabolites of Ifosfamide can be reduced when Ifosfamide is used in combination with Voriconazole resulting in a loss in efficacy.
WarfarinIfosfamide may increase the anticoagulant activities of Warfarin.
ZafirlukastThe metabolism of Ifosfamide can be decreased when combined with Zafirlukast.
ZiprasidoneThe serum concentration of the active metabolites of Ifosfamide can be reduced when Ifosfamide is used in combination with Ziprasidone resulting in a loss in efficacy.
Food InteractionsNot Available

Targets

1. DNA
Kind
Nucleotide
Organism
Human
Pharmacological action
yes
Actions
other/unknown
General Function:
Used for biological information storage.
Specific Function:
DNA contains the instructions needed for an organism to develop, survive and reproduce.
Molecular Weight:
2.15 x 1012 Da
References
  1. Furlanut M, Franceschi L: Pharmacology of ifosfamide. Oncology. 2003;65 Suppl 2:2-6. [PubMed:14586139 ]
  2. Hartley JM, Spanswick VJ, Gander M, Giacomini G, Whelan J, Souhami RL, Hartley JA: Measurement of DNA cross-linking in patients on ifosfamide therapy using the single cell gel electrophoresis (comet) assay. Clin Cancer Res. 1999 Mar;5(3):507-12. [PubMed:10100700 ]
  3. Willits I, Price L, Parry A, Tilby MJ, Ford D, Cholerton S, Pearson AD, Boddy AV: Pharmacokinetics and metabolism of ifosfamide in relation to DNA damage assessed by the COMET assay in children with cancer. Br J Cancer. 2005 May 9;92(9):1626-35. [PubMed:15827549 ]
  4. Lokiec F: Ifosfamide: pharmacokinetic properties for central nervous system metastasis prevention. Ann Oncol. 2006 May;17 Suppl 4:iv33-6. [PubMed:16702183 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,4-cineole 2-exo-monooxygenase.
Gene Name:
CYP2B6
Uniprot ID:
P20813
Molecular Weight:
56277.81 Da
References
  1. Lokiec F: Ifosfamide: pharmacokinetic properties for central nervous system metastasis prevention. Ann Oncol. 2006 May;17 Suppl 4:iv33-6. [PubMed:16702183 ]
  2. Chen CS, Jounaidi Y, Waxman DJ: Enantioselective metabolism and cytotoxicity of R-ifosfamide and S-ifosfamide by tumor cell-expressed cytochromes P450. Drug Metab Dispos. 2005 Sep;33(9):1261-7. Epub 2005 May 26. [PubMed:15919850 ]
  3. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  4. Roy P, Yu LJ, Crespi CL, Waxman DJ: Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles. Drug Metab Dispos. 1999 Jun;27(6):655-66. [PubMed:10348794 ]
  5. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitorinducer
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Lokiec F: Ifosfamide: pharmacokinetic properties for central nervous system metastasis prevention. Ann Oncol. 2006 May;17 Suppl 4:iv33-6. [PubMed:16702183 ]
  2. Chen CS, Jounaidi Y, Waxman DJ: Enantioselective metabolism and cytotoxicity of R-ifosfamide and S-ifosfamide by tumor cell-expressed cytochromes P450. Drug Metab Dispos. 2005 Sep;33(9):1261-7. Epub 2005 May 26. [PubMed:15919850 ]
  3. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  4. Roy P, Yu LJ, Crespi CL, Waxman DJ: Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles. Drug Metab Dispos. 1999 Jun;27(6):655-66. [PubMed:10348794 ]
  5. Preiss R, Schmidt R, Baumann F, Hanschmann H, Hauss J, Geissler F, Pahlig H, Ratzewiss B: Measurement of 4-hydroxylation of ifosfamide in human liver microsomes using the estimation of free and protein-bound acrolein and codetermination of keto- and carboxyifosfamide. J Cancer Res Clin Oncol. 2002 Jul;128(7):385-92. Epub 2002 Jun 11. [PubMed:12136253 ]
  6. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Lokiec F: Ifosfamide: pharmacokinetic properties for central nervous system metastasis prevention. Ann Oncol. 2006 May;17 Suppl 4:iv33-6. [PubMed:16702183 ]
  2. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  3. Roy P, Yu LJ, Crespi CL, Waxman DJ: Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles. Drug Metab Dispos. 1999 Jun;27(6):655-66. [PubMed:10348794 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Roy P, Yu LJ, Crespi CL, Waxman DJ: Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles. Drug Metab Dispos. 1999 Jun;27(6):655-66. [PubMed:10348794 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinducer
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Lokiec F: Ifosfamide: pharmacokinetic properties for central nervous system metastasis prevention. Ann Oncol. 2006 May;17 Suppl 4:iv33-6. [PubMed:16702183 ]
  2. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinducer
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
References
  1. Lokiec F: Ifosfamide: pharmacokinetic properties for central nervous system metastasis prevention. Ann Oncol. 2006 May;17 Suppl 4:iv33-6. [PubMed:16702183 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Exhibits a high coumarin 7-hydroxylase activity. Can act in the hydroxylation of the anti-cancer drugs cyclophosphamide and ifosphamide. Competent in the metabolic activation of aflatoxin B1. Constitutes the major nicotine C-oxidase. Acts as a 1,4-cineole 2-exo-monooxygenase. Possesses low phenacetin O-deethylation activity.
Gene Name:
CYP2A6
Uniprot ID:
P11509
Molecular Weight:
56501.005 Da
References
  1. Lokiec F: Ifosfamide: pharmacokinetic properties for central nervous system metastasis prevention. Ann Oncol. 2006 May;17 Suppl 4:iv33-6. [PubMed:16702183 ]
  2. Roy P, Yu LJ, Crespi CL, Waxman DJ: Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles. Drug Metab Dispos. 1999 Jun;27(6):655-66. [PubMed:10348794 ]
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP2C18
Uniprot ID:
P33260
Molecular Weight:
55710.075 Da
References
  1. Roy P, Yu LJ, Crespi CL, Waxman DJ: Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles. Drug Metab Dispos. 1999 Jun;27(6):655-66. [PubMed:10348794 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gastric epithelial cells, it is a key step in the generation of prostaglandins, such as prostaglandin E2 (PGE2), which plays an important role in cytoprotection. In platelets, it is involved in the gener...
Gene Name:
PTGS1
Uniprot ID:
P23219
Molecular Weight:
68685.82 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A7
Uniprot ID:
P24462
Molecular Weight:
57525.03 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23